Track topics on Twitter Track topics that are important to you
Full details of EXSCEL with the GLP-1 agonist exenatide, in which the agent didn't show any cardiovascular benefit over placebo in type 2 diabetes, provide "some good news" but also "some disappointment."
Medscape Medical News
Original Article: EXSCEL: 'Disappointment' Spurs Discussion on GLP-1 Agonists in DiabetesNEXT ARTICLE
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...